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Abstract
Objectives
Anma therapy (Japanese massage therapy, AMT) significantly reduces the severity of phys-
ical complaints in survivors of gynecologic cancer. However, whether this reduction of
severity is accompanied by improvement in health-related quality of life is unknown.
Methods
Forty survivors of gynecologic cancer were randomly allocated to either an AMT group that
received one 40-min AMT session per week for 8 weeks or a no-AMT group. We prospec-
tively measured quality of life by using the Japanese version of the European Organization
for Research and Treatment of Cancer QLQ-C30 version 3.0 (EORTC QLQ-C30) at base-
line and at 8-week follow-up. The QLQ-C30 response rate was 100%. Hospital Anxiety
Depression Scale (HADS), Profile of Mood States (POMS), and Measure of Adjustment to
Cancer were also prespecified and prospectively evaluated.
Results
The QLQ-C30 Global Health Status and Quality of Life showed significant improvement at 8
weeks (P = 0.042) in the AMT group compared with the no-AMT group, and the estimated
mean difference reached a minimal clinically important difference of 10 points (10.4 points,
95% CI = 1.2 to 19.6). Scores on fatigue and insomnia showed significant improvement in
the AMT group compared with the no-AMT group (P = 0.047 and 0.003, respectively). There
were no significant between-group improvements in HADS anxiety and depression scales;
however, POMS-assessed anger-hostility showed significant improvement in the AMT
group compared with the no-AMT group (p = 0.028).
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Conclusions
AMT improved health-related quality of life in gynecologic cancer survivors. AMT can be of
potential benefit for applications in oncology.
Introduction
Cancer survivors experience adverse effects years into survivorship [1]. In many studies, the
most prevalent physical symptoms reported in cancer survivors are fatigue [1–4], pain [2–4],
stress [1,2,4], insomnia [1,2,4], weight gain [1], and lymphedema [4], and the most prevalent
psychological symptoms reported are depression [2–6] and anxiety [3–6]. Survivors struggle
with symptom burden long into survivorship [5] and cancer survivors experience fear of can-
cer recurrence [1,7,8]. Thus, the physical symptoms and psychological state of cancer survivors
during survivorship might significantly affect quality of life (QOL).
Anma massage therapy (Japanese massage therapy, AMT) is a popular form of complemen-
tary and alternative medicine in Japan. Based on anecdotal information, it has long been used
to relieve physical and psychological complaints in healthy persons as well as in persons with
cancer-related symptoms. However, until recently, scientific evidence of the effectiveness of
AMT for patients with cancer or cancer survivors has been lacking.
To examine the physical and psychological effects of AMT in survivors of gynecologic can-
cer, after a preliminary study [9], we designed [10] and conducted [11] a randomized, two-
arm, parallel-group, controlled trial over a two-year period. In this study, we confirmed that
AMT significantly reduces severity of physical complaints in survivors of gynecologic cancer.
AMT also changes the values of certain biochemical markers, possibly by inhibiting the sympa-
thetic nervous system [11]. However, whether this reduction in severity is accompanied by
improved health-related QOL (HR-QOL) is not known. Therefore, here we report the effect of
AMT on HR-QOL outcomes for survivors of gynecologic cancer.
Materials and methods
Trial registration
On October 12, 2012, this trial was registered with the UMIN Clinical Trials Registry as
application UMIN000009097: Effects of continuous traditional Japanese massage therapy
(Anma therapy) for cancer survivors: a randomized controlled trial (https://upload.umin.ac.
jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=
R000010670&language=E). The CONSORT checklist for this trial is available in S1 Checklist.
Ethics statements
The Medical Ethics Committee of Tsukuba University of Technology, Japan, approved this
trial on September 27, 2012 (Approval No. 5). Participants were recruited by trial gynecologists
working at another hospital and were provided with trial information (oral and written) at the
coordinating office of Tsukuba University of Technology. They subsequently submitted a writ-
ten consent form to participate in the trial by hand or via facsimile. Submission of a consent
form was considered to be enrolment. This trial was conducted according to the principles of
the Helsinki Declaration.
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Study overview
Recruitment began on October 13, 2012. The first participant’s trial began on November 2,
2012 and the last participant’s final 8-week follow-up session was on November 1, 2014. As
described previously [10,11], we enrolled in this trial 40 participants who met the following
inclusion criteria: (a) a history of uterine-cervical, endometrial, ovarian, fallopian-tubal, or
peritoneal cancer; (b) no recurrence of such cancer for 3 years; (c) age 20 years; and (d)
confirmed eligible for the trial by the gynecologist responsible for the patient.
After enrollment was completed, randomization was done with an allocation sequence gen-
erated by block randomization by the trial statistician. However, allocation adjustment factors
were not set in the trial due to insufficient information about factors influencing the effective-
ness of AMT. Before commencement of the trial, a table of randomized assignment was cre-
ated by the same statistician and managed by two employees at the trial’s coordinating office;
participants were randomly allocated to an AMT group or no-AMT group.
AMT treatment involved a once-weekly 40-min AMT session for 8 consecutive weeks.
According to AMT protocol [11], AMT participants received a full-body massage that utilized
standard AMT techniques [12] and focused on specific locations related to their physical com-
plaints. All outcomes were assessed before the first session (pre-session, baseline) and before the
final session (8-week follow-up) to verify the effects of 8 consecutive weeks of weekly AMT.
Some outcomes were also assessed after the first session (post-session) to confirm the immediate
effects of single-session AMT. No-AMT participants did not receive AMT and were followed as
usual by their medical doctors, although on the first day, they met with a massage therapist for a
40-min semi-structured chat intervention. The chat intervention included self-disclosure [13],
positive thinking [14], and use of a positive feedback method. This chat protocol was previously
reported in detail [11]. All outcomes were assessed before the chat session (pre-session, baseline)
and some outcomes were also assessed again after the session (post-session). On the final day of
the 8-week trial, the no-AMT participants returned to the office for assessment (8-week follow-
up) and a single 40-min AMT session as a gift for participating in the study.
Assessments
We prespecified four instruments to clarify the effects of AMT on patient-reported outcomes:
the Japanese versions of the European Organization for Research and Treatment of Cancer
QLQ-C30 version 3.0 (EORTC QLQ-C30), Hospital Anxiety Depression Scale (HADS), Pro-
file of Mood States (POMS), and Measure of Adjustment to Cancer (MAC).
We assessed HR-QOL in patients using the Japanese version of the EORTC QLQ-C30 ver-
sion 3.0. The reliability and validity of this scale has been established and it has been used
internationally in a wide range of cancer clinical trials [15]. This scale is a 30-item self-reported
Likert method questionnaire that is divided into three subcategories: global health status/QOL
(2 items); functional scales, including five subscales (physical functioning, 5 items; role func-
tioning, 2 items; emotional functioning, 4 items; cognitive functioning, 2 items; and social
functioning, 2 items); and symptom scales, including nine subscales (fatigue, 3 items; nausea
and vomiting, 2 items; pain, 2 items; dyspnea, 1 item; insomnia, 1 item; appetite loss, 1 item;
constipation, 1 item; diarrhea, 1 item; and financial difficulty, 1 item). Linear transformation
was applied to each subscale to standardize the raw score so that scores range from 0 to 100,
with higher scores representing better levels of global health status and functioning and lower
scores representing a worsening of symptoms [16]. In this study, we regarded a difference of
10 points or more on the QLQ-C30 score as clinically meaningful [17,18].
The 14-item HADS scale was developed to measure anxiety (7 items) and depression (7
items) in patients with cancer, utilizing a 4-point Likert scale ranging from 0 to 3, with lower
Health-related quality of life after Anma therapy
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scores representing lesser degrees of anxiety/depression [19]. The scale’s reliability and validity
has been established for use in Japanese patients [20].
The brief 30-item Japanese version of the original 65-item POMS scale developed by
McNair et al. [21] assesses temporal mood states that change according to condition and
allows simultaneous assessment of six subscales: tension-anxiety, depression-dejection, anger-
hostility, vigor, fatigue, and confusion. Questions were decreased to 30 items to reduce subject
burden and allow assessment of changes in mood and emotion over a long time window. The
brief version’s reliability and validity has been established and found to be capable of obtaining
the same results as the 65-item original version [22]; therefore, it is used widely in many study
fields in Japan. In the brief version, each subscale is evaluated with five items on a 5-point
Likert scale (0 to 4). Moreover, a total mood disturbance score can be calculated by subtracting
the vigor score from the sum of the remaining five subscales. The higher the vigor score and
lower the other five subscale scores and total mood disturbance score, the better the mood
state.
The MAC scale is a 40-item questionnaire developed by Watson et al. [23] to measure cop-
ing responses in patients with cancer. The reliability and validity of the Japanese version has
been established [24]. This scale utilizes a 4-point Likert scale (1 to 4) and comprises five sub-
scales on coping styles: fighting spirit (16 items), helplessness/hopelessness (6 items), anxious
preoccupation (9 items), fatalism (8 items), and avoidance (1 item). The higher the score in
fighting spirit, the more patients tend to exhibit that coping style; whereas the lower the score
of the other subscales, the more patients tend to exhibit the relevant coping style.
Statistical methods
Statistical analysis including how the sample size was determined has been described previ-
ously [10,11]. In this study, we defined a modified intention-to-treat (mITT) analysis set,
which consisted of all participants who were treated at least once in the AMT arm and all par-
ticipants who attended the single chat intervention in the no-AMT arm.
For the summary of baseline characteristics, categorical data are presented as frequencies
and percentages. Continuous data are presented as medians and ranges. Continuous variables
were compared using the Mann-Whitney U test. Categorical variables were examined using
Pearson’s chi-square test with continuity correction.
All scales were summarized using medians and interquartile ranges. We compared AMT
and no-AMT group scores using the Mann-Whitney U test for changes in scores from pre-ses-
sion measurements to 8-week follow-up measurements. Exact p-values were calculated to
address issues with small sample sizes and tied scores. We also calculated two-sided 95% exact
Hodges-Lehmann confidence intervals for median differences between groups. The mean dif-
ference of Global Health Status/QOL in EORTC QLQ-C30 scale and its 95% confidence inter-
val was calculated and compared to a minimal clinically important difference of 10 points
[17,18]. We visually confirmed the normality of the Global Health Status/QOL changes by
using Q-Q plots. We also applied the same analyses to the POMS scales to examine changes in
scores from pre-session to post-session.
All P-values were two-sided, and the level of statistical significance was set at 0.05. Multi-
plicity issues were not considered. SAS 9.4 (SAS Institute, Cary, NC) was used for all analyses.
Results
Baseline characteristics
Among 58 eligible participants, we enrolled 40 who submitted the consent form. Twenty par-
ticipants were randomized to the AMT group and 20 to the no-AMT group. One participant
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who had been randomized to the no-AMT group received AMT intervention (Fig 1 [11], S1
Fig). Demographic and clinical variables were well-balanced between the AMT and no-AMT
groups [11] (Table 1). All participants completed their interventions and provided responses.
EORTC QLQ-C30. On the Global Health Status/QOL scale, the AMT group compared
with the no-AMT group showed significant improvement at 8 weeks (median scores, from 75
to 83 and from 79 to 67, respectively; P = 0.042), and the estimated mean difference reached a
minimal clinically important difference of 10 points (10.4 points, 95% CI = 1.2 to 19.6) (Fig 2,
Table 2). In functioning scales, we found no significant between-group differences (Table 2).
In symptom scales, scores on fatigue and insomnia showed significant improvement in the
AMT group compared with the no-AMT group at 8 weeks (median scores of fatigue, from 33
to 28 and from 22 to 33, respectively [P = 0.047]; median scores of insomnia, from 33 to 0 and
from 0 to 17, respectively [P = 0.003]). In other symptom scales, between-group differences
were not significant at 8 weeks (Table 3).
HADS. We found no significant between-group difference in scores for HADS anxiety
(median scores, from 6 to 5 and from 5 to 6, respectively; P = 0.256) or HADS depression (median
scores, from 4 to 3 and from 4 to 4, respectively; P = 0.282) over the 8-week trial (Table 4).
POMS. Anger-hostility in the AMT group compared with the no-AMT group showed sig-
nificant improvement at 8 weeks (median scores, from 2 to 1 and from 0 to 0, respectively;
P = 0.028) (S1 Table). In other scales, between-group differences were not significant at 8
weeks. We found significant between-group differences in score changes from pre-session to
post-session for anger-hostility (median scores, from 2 to 0 and from 0 to 0, respectively;
P = 0.044), confusion (median scores, from 5 to 2 and from 4 to 4, respectively; P = 0.036), and
Fig 1. CONSORT flowchart of participant recruitment [11]. AMT: Anma massage therapy.
https://doi.org/10.1371/journal.pone.0196638.g001
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total mood disturbance (median scores, from 5 to -8 and from 5 to 1, respectively; P = 0.028).
Other scales showed no significant between-group differences (S1 Table).
MAC. No significant between-group differences were found in MAC score changes over
the 8-week trial (S2 Table).
Discussion
We have already confirmed that AMT significantly reduces the severity of physical complaints
as assessed by VAS in survivors of gynecologic cancer [11]. In the present study, the Global
Health Status/QOL was significantly improved in the AMT group and the estimated mean dif-
ference was clinically meaningful at 8 weeks. Also, scores on fatigue and insomnia were signifi-
cantly improved in the AMT group and the estimated mean difference of insomnia was
clinically meaningful. These findings suggest that reduced severity of physical complaints by
AMT are accompanied by improved HR-QOL, especially by alleviating insomnia.
Although other studies have reported significant improvements in insomnia by massage
therapies, some of these studies were based on different scales of insomnia, different massage
therapies, or included subjects with various types or stages of cancer [25–27]. Some studies
have reported that insomnia is one of the most prevalent physical symptoms in cancer survi-
vors [1, 2, 4], which might support our hypothesis that AMT improved HR-QOL by alleviating
insomnia.
Table 1. Demographics and baseline characteristics of cancer survivors.
Characteristic AMT (n = 20) No AMT (n = 20) P-valuea
Age, median (range) 53.0 (40–69) 55.5 (41–75) 0.600
Age at cancer onset, years, median (range) 42.5 (33–59) 43.5 (26–70) 0.677
Duration from cancer onset, years, median (range) 8.3 (3.1–21.3) 8.6 (3.2–27.8) 0.798
Site of gynecologic cancer
Uterine cervix 11 (55%) 14 (70%) 0.340
Endometrium 7 (35%) 3 (15%)
Ovary 2 (10%) 3 (15%)
FIGO stage
I 13 (65%) 15 (75%) 0.730
II-IV 7 (35%) 5 (25%)
Surgery
Yes 20 (100%) 17 (85%) 0.230
No 0 (0%) 3 (15%)
Lymph node dissection
Yes 16 (80%) 14 (70%) 0.715
No 4 (20%) 6 (30%)
Chemotherapy
Yes 6 (30%) 5 (25%) >0.999
No 14 (70%) 15 (75%)
Radiotherapy
Yes 8 (40%) 5 (25%) 0.500
No 12 (60%) 15 (75%)
AMT = Anma therapy.
aP-values were calculated by Mann-Whitney U test for continuous variables, Pearson’s chi-square test for categorical
variables, and continuity corrections were performed for two-by-two tables.
https://doi.org/10.1371/journal.pone.0196638.t001
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Previous studies have indicated that cancer survivors experience anxiety [3–6] and depres-
sion [2–6]. However, in the present study, baseline medians of HADS anxiety and HADS
depression in both AMT and no-AMT groups corresponded to the same categories as mentally
healthy Japanese (cut-off points: 10 for anxiety and 5 for depression) [28]. This might account
for our inability to confirm a reduction in participants’ anxiety and depression after AMT.
Several recent studies have reported improved mood after massage in patients with cancer,
although the method used in some studies to assess and confirm this was based on different
scales, different massage therapies, or included subjects with various stages of cancer [29–33].
Our results are very similar to those reported in previous studies using POMS assessment: sig-
nificant improvement in anger-hostility and total mood disturbance after massage [34]; imme-
diate and significant decreased mood disturbance compared to a control group [35]; and less
anger-hostility after longer-term massage [36]. Moreover, a meta-analysis including 18 RCTs
(950 breast cancer patients in total) revealed no significant improvement in depression and
anxiety, although it did find significant improvement in anger by massage compared with con-
trol interventions [37]. The psychological/emotional results of the present study clearly sup-
port our findings.
For patients with cancer, coping with the disease is an important determinant of psycholog-
ical morbidity, QOL, and treatment adherence [38]. Poor coping responses (i.e., low fighting
spirit, high anxious preoccupation, high fatalism, and high helplessness/hopelessness) were
found to be significant determinants of psychiatric morbidity in ambulatory breast cancer
patients [39]. Patients with ovarian cancer who used massage therapy were found to have sig-
nificantly lower hopelessness [40]. However, in this study, we found no significant differences
Fig 2. Changes in Global Health scores measured by using the EORTC QLQ-C30. AMT = Anma massage therapy.
https://doi.org/10.1371/journal.pone.0196638.g002
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in any MAC scale score over the 8-week trial period. Further studies are needed to investigate
this point.
This study has some limitations. First, participants might have been psychologically healthy
and without serious symptoms such as nausea and vomiting, dyspnea, appetite loss, or finan-
cial difficulty as measured by the EORTC QLQ-C30 (Tables 2 and 3). It could be that they
were comparatively long-term survivors without recurrence at the time of the trial. It is also
possible that questionnaires such as the HADS, MAC, and EORTC QLQ-C30—each devel-
oped specifically to target patients with cancer—were not suitable to verify the effects of AMT
on the mindset and HR-QOL of the present participants.
Second, as this was the first registered RCT on the effects of AMT and given the absence of
basic scientific data, medical doctors had difficulty recruiting patients with cancer currently
receiving medical treatment. Third, to generalize findings from this RCT, findings should be
verified by a multicenter RCT that utilizes carefully selected questionnaires, recruits a more
consistent population, and limits sample population characteristics (e.g., by tumor type, cancer
stage, duration from cancer onset, or target symptoms). Fourth, a precise no-AMT interven-
tion (control) might entail equal division between the two groups of the total amount of time
spent with a therapist. A subsequent RCT should reconsider the appropriate intervention
method for the control for AMT. Non-Anma relaxation practices such as yoga or meditation
might be a better intervention for the control group. Finally, this study was an open-label RCT
and subjective assessments were needed for most endpoints, which might lead to biased
results. For greater credibility of our findings, we need a double-blinded (to the extent possi-
ble) multicenter RCT with better active control intervention in the future.
In conclusion, as well as reducing the severity of physical complaints [11], continuous
once-weekly AMT over a period of 8 weeks improved the HR-QOL of gynecologic cancer
Table 2. Analyses of EORTC QLQ-C30 Global and functioning scales.
Scale (possible range) Statistics AMT (N = 20) No-AMT (N = 20) Difference (95% CI)a P-valueb
Global Health Status / QOL (0–100)
Baseline Median (IQR) 75 (63 to 83) 79 (67 to 83)
8-week follow-up Median (IQR) 83 (67 to 88) 67 (50 to 83) 8.3 (0.0 to 16.7) 0.042
Physical Functioning (0–100)
Baseline Median (IQR) 93 (87 to 100) 93 (87 to 100)
8-week follow-up Median (IQR) 93 (87 to 100) 93 (87 to 100) 0.0 (0.0 to 6.7) 0.755
Role Functioning (0–100)
Baseline Median (IQR) 100 (100 to 100) 100 (100 to 100)
8-week follow-up Median (IQR) 100 (100 to 100) 100 (100 to 100) 0.0 (0.0 to 0.0) 0.919
Emotional Functioning (0–100)
Baseline Median (IQR) 88 (71 to 92) 83 (67 to 96)
8-week follow-up Median (IQR) 79 (67 to 88) 79 (67 to 88) 0.0 (-8.3 to 8.3) 0.896
Cognitive Functioning (0–100)
Baseline Median (IQR) 67 (67 to 83) 67 (50 to 83)
8-week follow-up Median (IQR) 83 (67 to 92) 83 (67 to 83) 0.0 (0.0 to 16.7) 0.618
Social Functioning (0–100)
Baseline Median (IQR) 100 (100 to 100) 100 (100 to 100)
8-week follow-up Median (IQR) 100 (100 to 100) 100(100 to 100) 0.0 (NC to NC) 0.626
AMT = Anma therapy; CI = confidence interval; IQR = interquartile range; NC = not calculated for this problem with alpha = 0.05.
aMedian differences between groups and their exact Hodges-Lehmann 95% confidence intervals of 8-week QOL differences from baselines were calculated.
bExact P-values were calculated by Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0196638.t002
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survivors. It is noteworthy that our findings are very similar to those of Western clinical stud-
ies on massage, and implies that Japanese massage (AMT) has benefits in oncology similar to
those of common massage techniques reported in Western studies.
Table 3. Analyses of EORTC QLQ-C30 symptom scales.
Scale (possible range) Statistics AMT (N = 20) No-AMT (N = 20) Difference (95% CI)a P-valueb
Fatigue (0–100)
Baseline Median (IQR) 33 (22 to 44) 22 (11 to 33)
8-week follow-up Median (IQR) 28 (17 to 33) 33 (11 to 33) -11.1 (-22.2 to 0.0) 0.047
Nausea and vomiting (0–100)
Baseline Median (IQR) 0 (0 to 0) 0 (0 to 0)
8-week follow-up Median (IQR) 0 (0 to 0) 0 (0 to 0) 0.0 (NC to NC) 0.506
Pain (0–100)
Baseline Median (IQR) 17 (0 to 33) 8 (0 to 17)
8-week follow-up Median (IQR) 17 (0 to 33) 17 (0 to 17) 0.0 (0.0 to 0.0) 0.682
Dyspnea (0–100)
Baseline Median (IQR) 0 (0 to 17) 0 (0 to 17)
8-week follow-up Median (IQR) 0 (0 to 0) 0 (0 to 33) 0.0 (0.0 to 0.0) 0.277
Insomnia (0–100)
Baseline Median (IQR) 33 (0 to 33) 0 (0 to 0)
8-week follow-up Median (IQR) 0 (0 to 33) 17 (0 to 33) -33.3 (-33.3 to 0.0) 0.003
Appetite loss (0–100)
Baseline Median (IQR) 0 (0 to 0) 0 (0 to 0)
8-week follow-up Median (IQR) 0 (0 to 0) 0 (0 to 0) 0.0 (0.0 to 0.0) 0.226
Constipation (0–100)
Baseline Median (IQR) 33 (0 to 33) 0 (0 to 33)
8-week follow-up Median (IQR) 0 (0 to 33) 0 (0 to 33) 0.0 (0.0 to 0.0) 0.158
Diarrhoea (0–100)
Baseline Median (IQR) 0 (0 to 0) 0 (0 to 17)
8-week follow-up Median (IQR) 0 (0 to 0) 0 (0 to 17) 0.0 (0.0 to 0.0) 1.000
Financial difficulties (0–100)
Baseline Median (IQR) 0 (0 to 0) 0 (0 to 0)
8-week follow-up Median (IQR) 0 (0 to 0) 0 (0 to 0) 0.0 (NC to NC) 1.000
AMT = Anma therapy; CI = confidence interval; IQR = interquartile range; NC = not calculated for this problem with alpha = 0.05.
aMedian differences between groups and their exact Hodges-Lehmann 95% confidence. intervals of 8-week QOL differences from baselines were calculated.
bExact P-values were calculated by Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0196638.t003
Table 4. Analyses of Hospital Anxiety Depression Scale (HADS) scale.
Scale (possible range) Statistics AMT (N = 20) No-AMT (N = 20) Difference (95% CI)a P-valueb
HADS Anxiety (0–21)
Baseline Median (IQR) 6 (3 to 7) 5 (2 to 7)
8-week follow-up Median (IQR) 5 (2 to 7) 6 (3 to 8) -1.0 (-2.0 to 1.0) 0.256
HADS Depression (0–21)
Baseline Median (IQR) 4 (2 to 7) 4 (2 to 7)
8-week follow-up Median (IQR) 3 (2 to 5) 4 (3 to 7) -1.0 (-3.0 to 1.0) 0.282
AMT = Anma therapy; CI = confidence interval; IQR = interquartile range.
aMedian differences between groups and their exact Hodges-Lehmann 95% confidence intervals of 8-week QOL differences from baselines were calculated.
bExact P-values were calculated with the use of Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0196638.t004
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